Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
RDH055
- Development stage
- Preclinical
- Lead developer
- Apichope Pharmaceutical
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
RDH055 is an investigational small molecule drug candidate developed by Apichope Pharmaceutical for the treatment of digestive system diseases. Currently in the preclinical stage of development, the drug is formulated as an oral capsule. As a Class 1 innovative drug in the developer's pipeline, it is targeted toward gastrointestinal disorders, although its specific molecular target and mechanism of action have not been publicly disclosed. The asset represents part of Apichope's strategic focus on developing novel therapies for digestive, cardiovascular, and endocrine systems.
- Other names
- RDH055 capsuleRDH-055 capsuleRDH 055 capsule
Beyond the preview
Go deeper on RDH055.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on RDH055.